Benchmarking, Modeling and Analytic Services
RNA Advisors provides market research and financial modeling services to help our clients better understand and support key metrics and industry benchmarks that drive forecast, valuation, investment returns, and operating performance in Life Science and Healthcare companies, products and markets.
Buy-Side Due Diligence & Transaction Support
RNA Advisors supports investors and acquirers that are exploring investment opportunities in the life sciences and healthcare industries. We have supported buy-side clients involved in M&A ranging in size from pension plans to Venture Capital and Private Equity funds, to family offices and investors with an industry sub-sector focus (biotechnology, diagnostics, medical devices, digital health, […]
Sell-Side Due Diligence & Transaction Support
RNA Advisors supports life sciences and healthcare companies in the planning, preparation, and diligence stages of financings (debt and equity), mergers, acquisitions, and other transactions. We have supported sell-side clients ranging in size from newly formed companies to venture-backed entities to public companies as well as those with an industry sub-sector focus (biotechnology, diagnostics, medical […]
M&A Advisory
RNA Advisors supports merger and acquisition (M&A) evaluations, planning and transactions in the life sciences and healthcare industries. Our expertise in market research, financial modeling, transaction structuring, and strategic analysis supports our clients with their decision-making processes, and our experience in complex transaction situations facilitates smoother and more effective stakeholder management. We are well-versed in […]
Licensing and Partnering Advisory
RNA Advisors supports licensing, partnering and collaboration (including joint ventures) arrangements between parties in the life sciences and healthcare industries. Our expertise in market research, financial modeling, transaction structuring, and strategic analysis supports our clients in their internal processes surrounding licensing and partnering decision making, and our deep experience with complex transactions in life sciences […]
